COMPANY PROFILE

Microbot Medical creates and commercializes transformational micro-robotic medical technologies that can change the future of medicine.

VISION + INNOVATIONS

Our vision is to improve the quality of life of millions of patients globally by advancing micro-robotic technologies to perform surgical procedures within the human body, and offer physicians and their patients less invasive and more precise solutions.

The company’s innovations tap into one of the fastest-growing spaces in the medical field, the minimal invasive space. Microbot Medical develops micro-robotic medical devices that provide doctors and surgeons with new technological capabilities to improve a patient’s health, comfort and quality of life.

Microbot’s current technological platforms, ViRob, TipCAT and CardioSert, are comprised of highly advanced technologies from which the Company is currently developing its first product candidate: the Self-Cleaning Shunt, or SCS, for the treatment of hydrocephalus and normal pressure hydrocephalus. Microbot is focusing on the development of a multi generation pipeline portfolio utilizing its three technologies:

The ViRob technology is a revolutionary autonomous micro-robot designed to operate within natural and artificial lumens, which can be controlled remotely or from within the body. Its miniature dimensions allow it to navigate in different spaces within the human body, including blood vessels, the digestive tract and the respiratory system. Its unique structure gives it the ability to advance in tight spaces and execute turns as well as the ability to remain within the human body for prolonged time. Click here to learn more about ViRob.

TipCAT is a transformational self-propelled, flexible, and semi-disposable endoscope providing See & Treat capabilities within tubular lumens in the human body such as the colon, blood vessels, and the urinary tract. Its locomotion mechanism is perfectly suitable to navigate and crawl through natural and artificial tubular lumens, applying the minimal necessary pressure to achieve the adequate friction required for gentle, fast, and safe advancement within the human body. Click here to learn more about TipCAT.

CardioSert technology is a unique combination of a guidewire and microcatheter, technologies that are broadly used for endoluminal surgery. The CardioSert technology features unique steering and stiffness control capabilities, and it was originally developed to support interventional cardiologists in crossing the most complex lesions called chronic total occlusion (CTO) during percutaneous coronary intervention (PCI) procedures and has the potential to be used in other spaces and applications, such as peripheral intervention and neurosurgery. Click here to learn more about CardioSert™.

MANAGEMENT

Harel Gadot

PRESIDENTCHIEF EXECUTIVE OFFICER AND CHAIRMAN OF THE BOARD OF DIRECTORS

Mr. Gadot is a co-founder of Microbot Medical and has been serving as the CEO since its inception and the Chairman of the Board since 2013. He is also the Chairman of XACTRobotics Ltd., another promising medical robotics company, specializing in the field of needle steering for medical procedures such as biopsies. Until 2013, Mr. Gadot was a board member at ConTIPI Ltd. Which was acquired in 2012 by Kimberly Clark. Prior to founding Microbot Medical, Mr. Gadot served as a Worldwide Group Marketing Director at Johnson & Johnson (Ethicon Inc., Somerville NJ), overseeing the company’s global strategic marketing. Prior to this, he was the Regional Marketing Manager at Johnson & Johnson (Ethicon Inc., Paris, France), responsible for the strategic marketing for Europe, Middle East and Africa. During his tenure, both companies enjoyed continuous growth in revenues and new product launches. Prior to this, Harel held several management positions in marketing and sales at Johnson & Johnson Medical Israel. Mr. Gadot is a guest speaker for management and innovation courses at leading universities in the United States and Israel, and holds a Bachelor of Science (BS) from Siena College (USA) and a Master in Business Administration (MBA) from Manchester University (UK).

David Ben Naim

CHIEF FINANCIAL OFFICER

David Ben Naim is a CPA licensed in the State of Israel. During the past five years, Mr. Ben Naim has held the following positions: (i) from 2014 to the present, he has operated DBNFinancial, providing clients with full outsourcing financial and accounting services; (ii) from 2012 – 2014, he served as CFO of Insuline Medical Ltd, a public company organized under the laws of the State of Israel listed on the Tel-Aviv Stock Exchange (TASEINSL) focused on improving the performance of current insulin treatment methods. As CFO, Mr. Ben Naim reported to its CEO and worked closely with the Board and its various committees, planning and implementing the transition from the development stage into a TASE listed company and participating in the structure and raise of equity and debt capital, among other responsibilities; and (iii) from 2008 – 2011, Mr. Ben Naim served as CFO of Crow Technologies 1977 Ltd, public company traded on the OTCQB (CRWTF), with responsibilities for planning and implementation of corporate financial strategy, reporting to the CEO and working closely with the Board and its various committees.

simon_hi_res

Simon Sharon

CHIEF TECHNOLOGY OFFICER

Mr. Sharon is a seasoned medical device executive with over 30 years of industry experience. Prior to rejoining Microbot, Simon served as the Chief Technology Officer at MEDX Xelerator, an Israel-based medical device and digital health incubator with partners such as Boston Scientific Corporation and Intellectual Ventures. He was also the Chairman of the Scientific Board at XACT Robotics, a private Israeli company developing a novel platform robotic technology for needle steering in minimally invasive interventional procedures. Prior to this, Mr. Sharon held the position of Chief Operating Officer at Microbot Medical Ltd. before it became a publicly traded company. Prior to joining Microbot in 2013, Mr. Sharon was the Vice President of Research & Development with IceCure Medical, a TASE traded company developing a portfolio of cryogenic ablation systems. Prior to IceCure, he held roles of increasing responsibility at Rockwell Automation–Anorad Israel Ltd, a leading linear motor-based, precision positioning equipment manufacturer. Prior to Rockwell, Simon was the Research & Development Manager at Disc-O-Tech Medical Technologies Ltd., a private orthopedic venture that was acquired by Kyphon (currently part of Medtronic), and before this was the Research & Development Manager at CI Systems, a worldwide supplier of a wide range of electro-optical test and measurement equipment.

Danna Perlman

DIRECTOR, IP & STRATEGY DEVELOPMENT

Danna brings over 10 years of experience in Intellectual Property strategy and development in the medical devices field. Prior to joining MEDX, Danna was a leading member of the in-house IP team at Medingo Ltd., a medical device company which was acquired by Roche in 2010. During her tenure at Medingo, Danna successfully managed dozens of patent applications throughout their entire life cycle, from draft to grant, including active management of patent prosecution processes in various countries worldwide. Danna also played a key role in several complex Freedom-to-Operate analyses. Prior to Medingo, Danna was an associate attorney at Lavie, Michlin & Co., where she specialized in tort law. Danna served for 5 years, until 2018, as a member of the Board of Directors of Prize4Life, a nonprofit organization dedicated to accelerating the discovery of treatment and a cure for ALS. Danna holds an LL.B. in Law and a B.A. in Economics, both from the University of Haifa, and has a background in Biomedical Engineering from the Technion – Israel Institute of Technology. Danna is licensed to practice law in Israel.

Kety Bardugo

QUALITY ASSURANCE MANAGER

Kety Bardugo Joined Microbot in August 2018. She is an experienced QA Manager with 15-year experience in the medical device industry. As a QA Manager, Kety was a point of contact for all Quality and Regulatory initiatives, including building and maintaining relationship with global Notified Bodies for the promotion of product registrations and leading European and FDA audits.

Prior to joining Microbot, Kety was QA Manager in Ossio, an orthopedic fixation company that provides a credible replacement to metal implants with an Intelligent Bone Regeneration Technology. Before Ossio, Kety was QA Manager at EndoChoice that developed innovative products and services for specialists treating a wide range of gastrointestinal (GI) conditions (sold to Boston Scientific) and QA specialist at Dune Medical and Lumenis.
Kety holds B.A in business administration and ICQE certification.

Eran Cohen

DIRECTOR OF BUSINESS DEVELOPMENT

Eran is an experienced executive and entrepreneur in the Life Sciences arena that co-founded and managed incubator-sponsored start-up companies in Israel. Prior to joining Microbot, Eran held senior Marketing & Business Development positions in Estar Medical (technologies and systems for the Regenerative Medicine arena), Beleaf Herbal (herbal supplements for the treatment of obesity, erectile dysfunction, diabetes and a range of skin and hair conditions) and Accellta Ltd (transformational technology for mass production of human embryonic and induced pluripotent stem cells, progenitors and differentiated cells for clinical and industrial applications). Eran serves as a business associate of Sama Brasil Comércio Internacional Ltda., a business development and trade company located in Brazil. Eran holds a BSc from the Hebrew University in Jerusalem and MBA from the Technion, Haifa.

BOARD OF DIRECTORS

Harel Gadot

PRESIDENTCHIEF EXECUTIVE OFFICER AND CHAIRMAN OF THE BOARD OF DIRECTORS

Mr. Gadot is a co-founder of Microbot Medical and has been serving as the CEO since its inception and the Chairman of the Board since 2013. He is also the Chairman of XACTRobotics Ltd., another promising medical robotics company, specializing in the field of needle steering for medical procedures such as biopsies. Until 2013, Mr. Gadot was a board member at ConTIPI Ltd. Which was acquired in 2012 by Kimberly Clark. Prior to founding Microbot Medical, Mr. Gadot served as a Worldwide Group Marketing Director at Johnson & Johnson (Ethicon Inc., Somerville NJ), overseeing the company’s global strategic marketing. Prior to this, he was the Regional Marketing Manager at Johnson & Johnson (Ethicon Inc., Paris, France), responsible for the strategic marketing for Europe, Middle East and Africa. During his tenure, both companies enjoyed continuous growth in revenues and new product launches. Prior to this, Harel held several management positions in marketing and sales at Johnson & Johnson Medical Israel. Mr. Gadot is a guest speaker for management and innovation courses at leading universities in the United States and Israel, and holds a Bachelor of Science (BS) from Siena College (USA) and a Master in Business Administration (MBA) from Manchester University (UK).

Yossi Bornstein

DIRECTOR AND CO-FOUNDER

Mr. Bornstein is a co-founder of Microbot Medical and has been a member of the Board of Directors since the inception of the company. Mr. Bornstein is the owner and President of Shizim Ltd., a life science holding group in Israel. Mr. Bornstein was the General Manager at Bristol-Myers Squibb (Israel) until 1992 when he joined the private sector. He is the founder of a number of privately held life-science companies including Pharmateam Ltd., which was sold in 2000. Mr. Bornstein was the Biotechnology Committee Chairman of USISTC (Unites States-Israel Science & Technology Commission) as well as a consultant for USISTF (Unites States-Israel Science & Technology Foundation). He is also the founder of ILSI-Israel Life Science Industry Organization and ITTN-Israel Tech Transfer Organization.

Martin J. Madden

DIRECTOR

Mr. Madden’s diversified and extensive R&D experience in the development of medical devices includes hundreds of projects in multiple medical spaces, many of which reached successful commercialization stage. Mr. Madden recently retired from Johnson & Johnson after a 30 year career. He first joined Johnson & Johnson in 1986 and held a number of roles of increasing importance, including Vice President Research & Development for Orthopedics, Global Surgery and Interventional Vascular Divisions. Mr. Madden holds an MBA from Columbia University, a Master of Science in Mechanical Engineering from Carnegie-Mellon University and Bachelor of Science in Mechanical Engineering from the University of Dayton.

Yoav Waizer, CPA

DIRECTOR

Yoav Waizer is an accomplished businessman with over 20 years of entrepreneurial experience working with private and publicly traded technology companies. As a partner and CFO at leading Israeli VC funds that include most recently Medica Venture Partners and previously, the Cedar Fund and Star Ventures, Yoav has worked with start-up companies from their very early stages all the way to successful exits. He has completed more than 70 initial portfolio investments from pre-seed to seed to later rounds, more than 175 investment rounds, 10 M&A transactions and 5 IPOs. His hands-on experience includes all aspects of finance and operations including tax planning and reporting, cash management, reporting to limited partnerships under US GAAP rules, investor relations, and has expertise in strategy, financial and legal due diligence, general and financial management, team-building, monitoring portfolio companies, raising capital and M&A.

Scott Burell

DIRECTOR

Scott R. Burell. Since August 2018, Mr. Burell is the Chief Financial Officer of Aivita Biomedical, Inc., an Irvine California-based immuno-oncology company focused on the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. From November 2006, Mr. Burell served as Chief Financial Officer, Secretary and Treasurer of CombiMatrix Corporation (NASDAQCBMX), a publicly traded diagnostics laboratory, until it was acquired by Invitae Corporation (NYSENVTA) in November 2017. Prior to this, Mr. Burell had served as CombiMatrix’s Vice President of Finance and Controller since February 2001. From May 1999 to February 2001, Mr. Burell was the Controller for Network Commerce, Inc., (NASDAQSPNW), which was a publicly traded technology and information infrastructure company located in Seattle. Prior to this, Mr. Burell spent nine years with Arthur Andersen’s Audit and Business Advisory practice in Seattle. During his tenure in public accounting, Mr. Burell worked with many clients, both public and private, in the high-tech and healthcare markets, and was involved in numerous public offerings, spin-offs, mergers and acquisitions. Mr. Burell is also a member of the Board of Directors of CollPlant Holdings Ltd., (NASDAQCLGN), an Israeli-based regenerative medicine company, and AgEagle Aerial Systems, Inc. (NYSEUAVS), a U.S.-based agricultural drone company. Mr. Burell obtained his Washington state CPA license in 1992 (currently inactive). He holds Bachelor of Science degrees in Accounting and Business Finance from Central Washington University.

P. (Laxmin) Laximarain

DIRECTOR

Mr. Laxminarain is a successful medical device executive with over 30 years’ experience and proven track record, most recently served as Worldwide President of Codman Neurosurgery (a Johnson & Johnson company), which was acquired by Integra LifeSciences Holdings Corporation in October 2017 for approximately $1.045 billion. Mr. Laxminarain first joined Johnson & Johnson in 1986 where he held roles of increasing responsibility, including President of Codman Neurosurgery from 2006 to 2017. In addition, Mr. Laxminarain held senior medical device positions in India, Singapore and South Korea. Prior to Johnson & Johnson, he was a management consultant with AF Ferguson & Co., an audit and management consultancy business in India where he worked on strategy as well as execution related projects in a variety of industries. Mr. Laxminarain received an MBAfrom the Indian Institute of Management.

SCIENTIFIC ADVISORY BOARD

Prof. Moshe Shoham

SCIENTIFIC DIRECTOR

Prof Shoham is also the founder of Mazor Robotics Ltd, (Nasdaq: MZOR), a growing medical device company in the field of surgical robotics, recently sold to Medtronic for $1.6 Billion Prof. Shoham is the inventor of the company’s technologies and is a co-founder of the Company. Prof. Shoham is a worldwide acclaimed authority on the field of robotics and has been conducting research in this field for over 25 years with special focus on kinematics and dynamics of robots, sensor integration and medical applications. Prof Shoham is the head of the robotics lab at the Technion’s faculty of Mechanical Engineering. Prof. Shohan was formerly the director of the robotic laboratory of the Department of Mechanical Engineering at Columbia University in NY. Prof Shoham is also the founder of Mazor Surgical Technologies Ltd, (Nasdaq: MZOR), a growing medical device company in the field of surgical robotics. Prof Shoham has published over 150 conference and journal papers and he is the author of three books.

simon_hi_res

Simon Sharon

CHAIRMANSCIENTIFIC ADVISORY BOARD

Mr. Sharon is a seasoned medical device executive with over 30 years of industry experience. Prior to rejoining Microbot, Simon served as the Chief Technology Officer at MEDX Xelerator, an Israel-based medical device and digital health incubator with partners such as Boston Scientific Corporation and Intellectual Ventures. He was also the Chairman of the Scientific Board at XACT Robotics, a private Israeli company developing a novel platform robotic technology for needle steering in minimally invasive interventional procedures. Prior to this, Mr. Sharon held the position of Chief Operating Officer at Microbot Medical Ltd. before it became a publicly traded company. Prior to joining Microbot in 2013, Mr. Sharon was the Vice President of Research & Development with IceCure Medical, a TASE traded company developing a portfolio of cryogenic ablation systems. Prior to IceCure, he held roles of increasing responsibility at Rockwell Automation–Anorad Israel Ltd, a leading linear motor-based, precision positioning equipment manufacturer. Prior to Rockwell, Simon was the Research & Development Manager at Disc-O-Tech Medical Technologies Ltd., a private orthopedic venture that was acquired by Kyphon (currently part of Medtronic), and before this was the Research & Development Manager at CI Systems, a worldwide supplier of a wide range of electro-optical test and measurement equipment.

eric-leuthardt

Eric C. Leuthardt, MD

SCIENTIFIC DIRECTOR

Eric C. Leuthardt, M.D. is a neurosurgeon who is currently an associate professor with the Department of Neurological Surgery, and the Departments of Neurobiology, Biomedical Engineering, Mechanical Engineering and Material Sciences at Washington University in St. Louis. He is Director of the Center for Innovation in Neuroscience and Technology. He received his B.S. in Biology and Theology at St. Louis University in 1995 and received his M.D. at the University of Pennsylvania’s School of Medicine in 1999. He went on to complete his training at Barnes Jewish Hospital and Washington University in St. Louis in 2005 and then completed a combined fellowship in epilepsy and spinal surgery at the University of Washington in Seattle in 2006. His research has focused on neuroprosthetics – devices linked to the brain that may restore function to patients with motor disabilities. His work in the field of neuroprosthetics and neurosurgical devices has yielded him numerous accolades as a scientist, a neurosurgeon, and an inventor. Dr. Leuthardt uses an integrated approach by employing multiple domains of expertise ranging from biomedical engineering, clinical neurosurgery, mathematical modeling, complex signal analysis, and computer programming. In addition to numerous peer-reviewed publications, Leuthardt has over 1000 patents on file with the U.S. Patent and Trademark Office for medical devices and brain computer interface technologies. He is also the founder of five startup companies.

COMPANY MILESTONES

Microbot Medical is a medical device company specialized in the researching, designing, developing and commercializing of transformational micro-robotics medical technologies.

  • null

    In-vitro Study

    In-vitro study, which was performed at Wayne State University, supports the SCS™’s potential as a viable technology for preventing occlusion in shunts used to treat hydrocephalus.

  • null

    In-vivo Study

    In-vivo study, which was performed at Washington University School of Medicine in St. Louis, supports the initial safety profile of the Company’s SCS™ as a CSF catheter.

  • null

    Acquisition of CardioSert Ltd.

    Acquisition of a novel patented technology from CardioSert Ltd., providing the Company with CardioSert™’s innovative technology, including R&D information, technical know-how and intellectual property. “The completion of this exciting and value-added acquisition, combined with our existing capabilities, global IP and recent preclinical results is expected to allow us to deliver highly differentiated robotic products to address some of today’s most unmet medical needs,” commented Harel Gadot, Chief Executive Officer, President and Chairman. “Our product development team has already completed the process of evaluating the CardioSert technology, and while leveraging our new and enhanced R&D facilities in Israel, we expect to move forward with new applications in the coming few months, continue focusing on our SCS device and building a multi-generation product pipeline.”

  • null

    Global Research & Development Facility

    Relocated its global Research & Development facility to the Caesarea Business and Industrial Park, located in Caesarea, Israel. The new 6,000 square feet facility houses the Company’s entire Israel operations, including engineering, research, prototype manufacturing, clinical and commercial teams and includes a laboratory with a clean area to allow small scale production, as well as evaluating and supporting the development of new concepts around micro-robotics medical products.